Table 1.

Study eligibility.

	Criteria
Participants	Adult and pediatric individuals affected by or at higher risk of developing PNH attacks, aHUS, rgMG, aAMR episodes, or DGF.
Interventions	Commercial C5 inhibitors (e.g., eculizumab, ravulizumab) and C1-inhibitors (e.g., Berinert®, Cinryze®, Haegarda®, Ruconest®).
Comparisons	Placebo, pre-/off-treatment state, historical cohorts that did not receive the interventions, and any other therapeutic strategy (e.g., SOC) including active drugs when it was considered as comparators in the eligible studies.
Type of study	RCT including their extension follow-up studies/post-hoc analyses, in addition to historically controlled interventional studies and other non-randomized (single arm) clinical trials.
	Real-life NRSI (e.g., registry studies and other real-world data studies).

Abbreviations: aHUS, atypical hemolytic uremic syndrome; aAMR, acute antibody-mediated rejection; DGF, delayed graft function; NRSI, non-randomized studies of the effects of interventions; PNH, paroxysmal nocturnal hemoglobinuria; RCT, randomized controlled trial; rgMG, refractory generalized myasthenia gravis; SOC, standard of care.